Tetra Radar · FDA Approvals · Decision date
Praxis Precision Medicines, Inc.: FDA decision date
Praxis Precision Medicines, Inc. (PRAX) · 27 December 2026
In June 2026, the FDA notified us that it had extended by three months the review period for our NDA for relutrigine, setting an updated PDUFA action date of December 27, 2026.
Source: 10-Q of 9 November 2026
The decision is pending.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.